降脂颗粒治疗血脂异常的临床观察

发布时间：2017-12-30 20:24

本文关键词：降脂颗粒治疗血脂异常的临床观察　出处：《时珍国医国药》2017年03期 　论文类型：期刊论文

【摘要】：目的观察降脂颗粒治疗血脂异常患者的临床疗效。方法将120例患者随机分为两组,治疗组60例,予降脂颗粒治疗;对照组60例予瑞舒伐他汀钙片或非诺贝特胶囊治疗。3个月为1个治疗疗程,3个月后分别观察临床疗效、血脂水平变化情况及中医证候疗效。结果治疗组总有效率96.66%,对照组总有效率93.33%,两组总有效率比较差异无统计学意义(P0.05);两组总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDLC)水平治疗前后组内比较,均有统计学意义(P0.05),两组治疗后组间比较差异无统计学意义(P0.05)。治疗组中医证候总有效率86.67%,对照组73.34%,两组总有效率比较差异有统计学意义(P0.05),说明治疗组中医证候疗效优于对照组。结论降脂颗粒具有降脂调脂作用。
[Abstract]:Objective To observe the clinical curative effect of patients with abnormal lipid granules in the treatment of blood lipids. Methods 120 patients were randomly divided into two groups, 60 cases in the treatment group, treated with Jiangzhi granule treatment; 60 patients in control group were given treatment of Rosuvastatin Calcium Tablets or Fenofibrate Capsules.3 month is 1 treatment course, don't observe the clinical curative effect of 3 months later, the changes in blood lipid levels the situation and effect of Chinese medicine. Results the total effective rate of treatment group 96.66%, control group total effectiveness 93.33%, two groups was no significant difference between the two groups (P0.05); total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (the level of LDLC) compared before and after treatment group were statistically significant (P0.05), the two groups had no statistically significant difference between the two groups after treatment (P0.05). The symptoms of the treatment group the total efficiency of 86.67%, control group 73.34%, two groups of the total efficiency difference There were statistical significance (P0.05), indicating that the curative effect of TCM syndrome in the treatment group was better than that of the control group. Conclusion Jiangzhi granule has the effect of lowering lipid and lipid regulating.

【作者单位】：鄂东医疗集团黄石市中医医院;
【分类号】：R259
【正文快照】： 血脂异常是身体大中动脉粥样硬化形成的关键因素,也是诱发心脑血管疾病的高危因素之一。当前,随着人们生活水平的显著提高,高血脂人群逐年增大,故心脑血管疾病发生率的随之上升。因此,研制出疗效更好、副作用更少、价格更便宜、患者更容易接受的降脂药物势在必行,并已成为医学

【相似文献】